Barbieri R, Ruisi G, Atassi G
Dipartimento di Chimica Inorganica, Università di Palermo, Italy.
J Inorg Biochem. 1991 Jan;41(1):25-30. doi: 10.1016/0162-0134(91)85005-2.
Bis(adeninato-N9)diphenyltin(IV) has been selected as a tumor panel compound by the U.S. National Cancer Institute and tested against a number of tumors according to standard protocols. The activity criteria were not passed. The solid state structure of the environment of tin in the complex has been definitely established to be of the tetrahedral type by means of 119Sn Mössbauer-Zeeman spectroscopy; this configuration has been assumed to be maintained also in aqueous suspensions of the drug, in conditions corresponding to the administration to mice. The occurrence of strong Sn-N bonds, consistently resistant to hydrolytic processes, has been assumed, and correlated to the observed low toxicity of the drug. The extent of the antitumor action corresponds to the standard response to Ph2SnIV moieties.
双（腺嘌呤-N9）二苯基锡（IV）已被美国国立癌症研究所选为肿瘤筛选化合物，并按照标准方案针对多种肿瘤进行了测试。该化合物未通过活性标准。通过119Sn穆斯堡尔-塞曼光谱法已明确确定该配合物中锡环境的固态结构为四面体类型；假定在与给小鼠给药相对应的条件下，该构型在药物的水悬浮液中也能保持。据推测，存在强Sn-N键，始终抗水解过程，并与观察到的药物低毒性相关。抗肿瘤作用的程度与对Ph2SnIV部分的标准反应相对应。
